🏛️ Verified NIH Record • Updated 2026-07-28

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy (NCT07498426)

A Phase III, Randomized, Placebo-controlled, Parallel Group, Double-blind Study to Evaluate the Efficacy and Safety of NIO752 in Participants With Progressive Supranuclear Palsy Followed by an Open Label Extension

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.

Who can join: Review the eligibility criteria below.

Location: Mayo Clinic Arizona — Scottsdale, Arizona

Age range: 41 Years to 81 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (42 Sites)

Showing the first 25 of 42 sites.

  • Mayo Clinic Arizona — Scottsdale, Arizona
  • Univ of California San Francisco — San Francisco, California
  • CenExcel Rocky Mtn Clin Research — Englewood, Colorado
  • Mayo Jacksonville — Jacksonville, Florida
  • Mayo Clinic — Rochester, Minnesota
  • Novartis Investigative Site — Westmead, New South Wales
  • Novartis Investigative Site — Melbourne, Victoria
  • Novartis Investigative Site — Shanghai,
  • Novartis Investigative Site — Suzhou,
  • Novartis Investigative Site — Caen,
  • Novartis Investigative Site — Créteil,
  • Novartis Investigative Site — Lille,
  • Novartis Investigative Site — Marseille,
  • Novartis Investigative Site — Nantes,
  • Novartis Investigative Site — Paris,
  • Novartis Investigative Site — Rennes,
  • Novartis Investigative Site — Toulouse,
  • Novartis Investigative Site — Munich, Bavaria
  • Novartis Investigative Site — Würzburg, Bavaria
  • Novartis Investigative Site — Bonn, North Rhine-Westphalia
  • Novartis Investigative Site — Düsseldorf, North Rhine-Westphalia
  • Novartis Investigative Site — Dresden, Saxony
  • Novartis Investigative Site — Leipzig, Saxony
  • Novartis Investigative Site — Beelitz,
  • Novartis Investigative Site — Berlin,

📞 Contact the Study Coordinator

Phone: (888) 669-6682

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗